Mytos

Mytos, founded in 2016 and headquartered in the United Kingdom, is at the forefront of scaling regenerative medicines to millions of patients. Their innovative iDEM robotics platform sits at the heart of a cutting-edge automated CDMO process, aiming to provide stem cell-derived therapies at a low cost.

The company has secured partnerships targeting various critical medical areas, including treating Parkinson's with neurons, repairing bones, restoring sight with corneal cells, and addressing hearing loss with auditory neurons. By 2027, Mytos anticipates its products will be entering clinical applications.

Having raised over $24M to date, including a recent $19M Series A round from investors such as Buckley Ventures, IQ Capital, and Wing Venture Capital, Mytos connects with influential founders from companies like Kite, Sana, Dropbox, and Revolut. The company's team is composed of elite engineers, alongside Nature-published scientists, driving innovation in biotechnology. Currently, Mytos is actively hiring to support its growth trajectory.